自体 CD5-KO 抗 CD5 CAR-T 细胞在复发/难治性 CD5⁺ 血液系统恶性肿瘤中的疗效与安全性

Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5(+) hematological malignancies.

CAR-T 细胞：改善儿童肿瘤结局所缺失的一环？

CAR T cells: the missing piece needed to improve outcomes for children with cancer?

CD5 消融通过减轻耗竭和促进细胞毒性，增强工程化 T 细胞的持久性和抗肿瘤效力

CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.

这些集体发现确立了 CD5 消融作为规避当前 T 细胞疗法固有局限性的可行策略，为临床转化提供了机制依据。

单细胞解析揭示 CD5 或 CD7 靶向 CAR-T 细胞治疗后的免疫失调

Single-Cell Dissection Reveals Immune Dysregulation After CD5 or CD7-Directed Chimeric Antigen Receptor T-Cell Therapy.

CCR4 表达定义了 T 细胞急性淋巴细胞白血病的一个可靶向亚群

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

复发/难治性 CD5 阳性弥漫大 B 细胞淋巴瘤的 CAR-T 细胞治疗较标准治疗产生更有利的结局

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.

靶向脂质纳米颗粒递送 FAP-CAR mRNA 实现强效体内 T 细胞工程化以对抗胰腺肿瘤

Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors.

出版商更正：异体 CD5 特异性 CAR-T 治疗复发/难治性 T-ALL：一项 I 期试验

Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.

CAR-T 细胞治疗 T 细胞来源的血液系统恶性肿瘤

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies.

靶向 CD5 的嵌合抗原受体工程化 NK 细胞抗 T 细胞恶性肿瘤

Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies.

第四代纳米抗体来源的抗 CD5 CAR-NK 细胞可能成为治疗 T 细胞恶性肿瘤的有前景的疗法。